Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

le metabolic effects in healthy subjects, together with the safety profile observed to date, suggest that LX4211 could be considered earlier in the diabetes treatment paradigm, perhaps including the potential treatment of pre-diabetes in patients with impaired glucose tolerance or impaired fasting glucose (IGT/IFG)."

About the Clinical Trial

The clinical trial was designed to assess the effect of different LX4211 dose schedules relative to meal time  in healthy subjects when taken as a single daily dose (400 mg) or a split dose (200 mg twice daily).  Subjects were randomized to LX4211 in an ordered sequence to assess the pharmacodynamic effects of different dosing times, ranging from 1 hour prior to meals to immediately prior to meals.  Pharmacodynamic effects, include urinary glucose excretion, fasting plasma glucose, insulin, PYY and GLP-1 (total and active) were assessed at multiple time points during the 12-day dosing period.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing o
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... N.J. , March 5, 2015 CANTEL MEDICAL ... for its second quarter ended January 31, 2015 on Thursday, ... call to discuss the results at 11:00 AM ET. ... 407-8033 approximately 5 to 10 minutes before the beginning of ... replay of the call will be available from Thursday, March ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... WALTHAM, Mass., Jan. 4, 2011 Syndax Pharmaceuticals, Inc., ... Horobin, M.D., the company,s president and CEO, will present ... 2011 at 10:00 a.m. PT at the Parc 55 ... include the recently reported results from a randomized phase ...
... Jan. 4, 2011 STAAR Surgical Company (Nasdaq: ... and marketer of minimally invasive ophthalmic products, today ... ICL implants in patients has exceeded 200,000.  Since ... used in refractive eye surgery as an alternative ...
Cached Medicine Technology:STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 2STAAR Surgical's Visian® ICL Surpasses 200,000 Implants 3
(Date:3/6/2015)... March 06, 2015 Dr. Amy Reed, who ... a ban on the use of power morcellators ( http://www.morcellatorlawsuit2015.com ... the cancer that prompted the launch of their public health ... week that the 41-year-old mother of six had recently undergone ... in her spine. Dr. Reed had been in remission for ...
(Date:3/6/2015)... March 06, 2015 Sanjay Gupta, ... deliver a keynote address at ATA 2015, the ... and Trade Show and world’s largest telemedicine, telehealth ... neurosurgeon, delivers medical correspondence for several of CNN’s ... and documentaries including his DuPont Award winning WEED ...
(Date:3/6/2015)... Ticket Down is a reliable source for authentic ... Clara, California. This state-of-the-art stadium opened on July 17, ... events. , The “Kick the Dust Up Tour” featuring country ... the west coast and Levi’s Stadium. The show at the ... August 29 and fans of the award-winning artist will be ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 ... the leader in the natural products coffee drinks category, ... 100 Cleanest Packaged Foods Awards for its Double ... puts packaged foods to the test to find the ... they must “taste absolutely delicious.” , “As a company ...
(Date:3/6/2015)... San Jose, California (PRWEB) March 06, 2015 ... cancer is one of the most common forms of ... women worldwide. Breast cancer can be screened through various ... among others. Mammography however remains the gold standard technique ... factors such as cost, time taken for the procedure, ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 2Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 3Health News:Power Morcellator News: Bernstein Liebhard LLP Comments on Report that Physician Working to Ban Uterine Morcellation Has Cancer Recurrence 4Health News:CNN’s Dr. Sanjay Gupta Among Headliners at American Telemedicine Association 2015 Annual Meeting 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 2Health News:Prevention Magazine Names Califia Farms Winner of 2015 Cleanest Packaged Food Award 3Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3
... removed from product -, WAYNE, N.J., May 19 ... of the liquid Leukine(R),(sargramostim) 500 mcg vial has been ... and is now available for patients and physicians,in the ... disodium),which was in the product,s liquid 500 mcg vial ...
... census, Americans office workers spend an average of 52 ... Many recent studies on job satisfaction have shown that ... under artificial light in windowless offices, report reduced job ... make office environments more conducive to productivity and employee ...
... initiation and progression of prostate cancer have eluded ... researchers have identified a specific gene expression profile ... for future treatments. The findings, published in BioMed ... genes that are differentially expressed in certain prostate ...
... VIEW, Calif., May 19 Alexza,Pharmaceuticals, Inc. ... Jeffrey S.,Williams has rejoined the company in ... Ltd., a wholly owned subsidiary of Alexza. ... the Alexza,subsidiary in Singapore and establishing potential ...
... LLC, the world,s,first mobile voice-activation solution for e-Health ... J. Zecchini as its Chief,Operating Officer and Chief ... be responsible for all operations and technology functions., ... to our MediVoice team," said,Anthony V. Milone, Board ...
... CLARA, Calif., May 19 FLARE Santa,Clara HIV ... (AACI), The Billy DeFrank Center Lesbian and Gay ... Health Department, Asian,& Pacific Islander Wellness Center present ... Thursday, May 22, 2008 from 11 to 2 ...
Cached Medicine News:Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 2Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 3Health News:Bayer Announces Availability of Reformulated Liquid Leukine(R) 4Health News:Greener offices make happier employees 2Health News:Mapping of prostate cancer genes opens the door to new treatments 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 2Health News:Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd. 3Health News:MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer 2
... SDS Recall marketing software enables the efficient ... The module also has many built-in time ... auto capitalization of name fields and numerous ... and accurate data input. The pre-defined options ...
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
Medicine Products: